Office of Drug Abuse

January The Nixon administration steps up the enforcement side of the drug effort by establishing the Office of Drug Abuse Law Enforcement. Its purpose is to establish joint federal and local task forces to fight street-level drug crime. 

Office of National Drug Control Policy. (2001). The economic costs of drug abuse in the United States, 1992-1998 (Publication No. NCJ-190636). Washington, DC Executive Office of the President. 

Marijuana is by far the most frequently abused illegal drug worldwide. The Office of National Drug Control Policy stated in its 2001 Annual Report that about 80% of Americans abusing illegal drugs used marijuana. The National Institute of Drug Abuse (NIDA), a branch of the National Institutes of Health (NIH), indicated in... 

Government Efforts. The epidemic of heroin abuse in the U.S. has led to considerable activity by Federal, State and Local Governments to deal with the problem. In the White House a Special Action Office for Drug Abuse Prevention was established. The FDA has exerted considerable effort In the area of policing drug treatment programs56 57,204, xhe National... 

In addition, if possible, die nurse obtains a history of any past drug or alcohol abuse. Individuals with a history of previous abuse are more likely to abuse odier drug s, such as the antianxiety drug s. Some patients, such as diose with mild anxiety or depression, do not necessarily require inpatient care. These patients are usually seen at periodic intervals in die primary health care provider s office or in a psychiatric outpatient setting. The preadministration assessments of the outpatient are the same as diose for the hospitalized patient. 

Seecof R, Tennant FS Subjective perceptions to the intravenous rush of heroin and cocaine in opioid addicts. Am J Drug Alcohol Abuse 12 79—87, 1987 Sees KL, Delucci KL, Masson C, et al Methadone maintenance vs. 180-day psycho-socially enriched detoxification for treatment of opioid dependence a randomized controlled trial. JAMA 283 1303-1310, 2000 Sells SB Treatment effectiveness, in Handbook on Drug Abuse. Edited by Dupont RE, Goldstein A, O Donnell J. Washington, DC, U.S. Government Printing Office, 1979, pp 105-118... 

Source. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, National Survey on Drug Use and Health, 2002 and 2003. 

National Institute on Drug Abuse and a grant from the Office of Naval... 

NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews, its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. 

Energy and supported by its Office of Health and Environmental Research. The research was also supported by awards from the National Institute on Drug Abuse to AM (DA 07515, DA 09158) and to ANG (DA 12412). 

Figure 7.1 Emergency department mentions of MDMA from 1994-2002. (Adapted from Office of Applied Studies, SAMSHA, Drug Abuse Warning Network, 2002 updated 03/2003.)...

Fig. 1. An overview of the DCLD tier/triage flow chart Boxes 1, 2, and 3 are taken from the Office of Device Evaluation decision tree, which is routinely used to determine whether a product can be reviewed as a 510(k) and found substantially equivalent to a predicate (currently marked) device or whether the product must be handled as a fundamentally new product and submitted to a PMA review. Box 4 determines the novelty of the product in terms of analyte, matrix, and/or technology. If new issues of safety and effectiveness are raised, a highly novel product might require review as a PMA. If the issues of safety and effectiveness are not new but require high-level scrutiny, then a tier III review is warranted. Examples of products requiring a tier III review would include 1. Analyte troponin for diagnosis of MI (with creatinine kinase as the predicate) 2. Matrix sweat patches for drugs of abuse (with urine drugs of abuse tests as the predicate) and 3. Technology nucleic acid...

---